SCHEDULE 13G/A: Venrock Funds Update Passive Stake in Spyre Therapeutics to 4.6%
Beneficial Ownership Update
Venrock Healthcare Capital Partners and affiliated entities have filed an amendment to their Schedule 13G, disclosing a collective beneficial ownership of 4.6% in Spyre Therapeutics, Inc. as of December 31, 2024.
Summary
- The filing is an Amendment No. 3 to Schedule 13G, updating the beneficial ownership of Spyre Therapeutics, Inc. Common Stock.
- The reporting persons are Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, who collectively form a group.
- As of December 31, 2024, the group beneficially owns an aggregate of 2,685,448 shares of Spyre Therapeutics, Inc. Common Stock.
- This ownership represents 4.6% of the Issuer's Common Stock outstanding.
- The percentage calculation is based on a total of 58,681,220 shares outstanding, which includes 51,431,220 shares as of November 1, 2024, and an additional 7,250,000 shares issued in a public offering on November 18, 2024.
- All reporting persons share both voting and dispositive power over the 2,685,448 shares.
- The filing certifies that the securities were acquired and are held for passive investment purposes and not to change or influence the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. This is a routine compliance filing updating beneficial ownership. The 4.6% stake is below the 5% threshold, which means the investor group is no longer required to file a Schedule 13D, indicating a passive investment strategy. While it implies a reduction from a previous 5%+ stake, the filing itself is a standard update.
Positives
- The continued holding of a significant stake (4.6%) by a specialized healthcare investment firm like Venrock Healthcare Capital Partners indicates ongoing confidence in Spyre Therapeutics, Inc.
Negatives
- The reported 4.6% stake is below the 5% threshold, which, for an amendment to a Schedule 13G, implies a reduction from a previously higher stake (likely 5% or more), potentially signaling a rebalancing or reduced conviction by the institutional investor.
Future Outlook
This Schedule 13G/A filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or the reporting persons' future investment intentions beyond their passive investment certification.
Industry Context
This filing reflects a routine update by a venture capital firm specializing in healthcare investments, Venrock Healthcare Capital Partners, regarding its passive stake in a therapeutics company. Such disclosures are standard practice for institutional investors managing their portfolio holdings and complying with SEC regulations.
Stakeholder Impact
- Shareholders: Provides transparency on a significant institutional investor's stake. The reduction below the 5% threshold (if applicable) might be interpreted by the market as a slight shift in the investor's position, though it remains a substantial holding.
Key Dates
| Date | Description |
|---|---|
| 2023-07-10 | Date of original Schedule 13G filing for Power of Attorney exhibits. |
| 2024-11-01 | Date of Issuer's Common Stock outstanding (51,431,220 shares) as reported in Form 10-Q/A. |
| 2024-11-18 | Date of Issuer's Quarterly Report on Form 10-Q/A filing and prospectus supplement for public offering. |
| 2024-11-19 | Date prospectus supplement for public offering was filed with the SEC. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting date for ownership). |
| 2025-02-14 | Date of execution of the Joint Filing Agreement and signing of the Schedule 13G/A. |
Keywords
Spyre Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G/A, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Healthcare Investment, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.